NewsBite

Biotech

Advertisement
Boston is an exception in the biotech world. While other centres struggle, the city’s biotechs are performing strongly.

Riding the scariest rollercoaster on the ASX

If you thought crypto investors need to have strong stomachs, spare a thought for the investors who try their luck in the biotech sector.

  • William Bennett

Latest

This week’s Bulls N’ Bears ASX Runner of the Week is … Hydration Pharmaceuticals.

Hydration rehydrates share price with non-US asset sale

This week’s Bulls N’ Bears Runner of the Week is … Hydration Pharmaceuticals. The company sold its non-US assets for a sum five times its market capitalisation.

  • Craig Nolan
Novo Nordisk’s diabetes and weight-loss drugs, Ozempic and Wegovy, have soared to celebrity status.

It introduced Ozempic to the world. Now it must remake itself

Danish drugmaker Novo Nordisk has eclipsed French luxury group LVMH to become Europe’s most valuable company – thanks to demand for diabetes and weight-loss drugs.

  • Eshe Nelson

The artificial heart set to transform medicine – and the Aussie who invented it

Biomedical engineer Daniel Timms lost his father to heart disease, but their kitchen-top tests helped him hone a radical idea.

  • Amanda Hooton

The April 20 Edition

The Aus-designed artificial heart set to revolutionise medicine | Preppers go mainstream | A sperm donor’s message to his progeny

Australian research has led to a number of highly-significant medical innovations.

Our track record in medical innovation can only be maintained with funding support

Australian researchers are responsible for a series of globally significant medical inventions and innovations.

  • The Herald's View
Advertisement
Jason Kovacic, executive director of the Victor Chang Cardiac Research Institute, said indirect funding was critical to research.

Future of medical research in doubt as question mark lingers over $45 million funding

The future of a government funding program which has assisted teams developing artificial hearts and turning spider venom into drug therapies is in doubt.

  • Mary Ward
Monash and the Alfred researchers are getting a $50 mil grant from the federal government to build the world’s first long-term artificial heart and get it to market by 2025. Til now, the race for a proper artificial heart underway since the old days of the spacerace has always fallen short. Prof David Kaye, Director of Cardiology at The Alfred, with the new artificial hearts. Picture by Wayne Taylor 19th February 2024

His dad was dying. So Daniel built a world-first artificial heart – with pipes and magnets

Australia will spend $50 million building the world’s first long-term artificial heart, after the original prototype was built with pieces bought from Bunnings.

  • Sherryn Groch
CSL chief executive Paul McKenzie.

Failed drug trial overshadows CSL’s bumper profits

Investors have punished the company’s share price for the second day in a row – despite it booking revenue of $12.3 billion for the half-year to December 31.

  • David Swan
Bill Mezzanotte said the study of CSL’s heart drug was the most ambitious in the company’s history.

Health behemoth CSL sheds $7b in value after heart drug fails trial

Shares in the blood plasma treatments maker were trading nearly 5 per cent lower following the results.

  • Millie Muroi

Original URL: https://www.brisbanetimes.com.au/topic/biotechnology-5v0